株探米国株
日本語 英語
エドガーで原本を確認する
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________
 
FORM 8-K
_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported):
July 26, 2022
 
USANA HEALTH SCIENCES, INC.
(Exact name of registrant as specified in its charter)

Utah
(State or other jurisdiction of incorporation)

001-35024
 
87-0500306
(Commission File No.)
 
(IRS Employer
Identification No.)
 
3838 West Parkway Boulevard
Salt Lake City, Utah 84120
(Address of principal executive offices, Zip Code) 
Registrant's telephone number, including area code: (801) 954-7100
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock, $0.001 par value per share
 
USNA
 
New York Stock Exchange
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02          Results of Operations and Financial Condition.

On July 26, 2022, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing its financial results for the second quarter ended July 2, 2022.  The release also announced that the Company will post a document titled “Management Commentary” on the Company’s website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call.  The Company noted that the call will consist of brief remarks by the Company’s management team, before moving directly into questions and answers. A copy of the press release, and the Management Commentary, are furnished herewith as Exhibits to this Current Report on Form 8-K and are incorporated herein by reference.  These documents will be posted on the Company’s corporate website, www.usana.com.

The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

Item 7.01          Regulation FD Disclosure

The information disclosed above under Item 2.02, as well as the exhibits attached under Item 9.01 below are incorporated herein by reference.

Item 9.01          Financial Statements and Exhibits.

(d)
Exhibits
Exhibit No.
 
Description
99.1
 
Press release issued by USANA Health Sciences, Inc. dated July 26, 2022 (furnished herewith).
     
99.2
 
Management Commentary provided by USANA Health Sciences, Inc. dated July 26, 2022 (furnished herewith).

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

USANA HEALTH SCIENCES, INC.





By:  /s/ G. Douglas Hekking                          

G. Douglas Hekking, Chief Financial Officer

Date:  July 26, 2022

Exhibit Index

Exhibit No.
 
Description
 
 

EX-99.1 2 a52792490ex991.htm EXHIBIT 99.1
 
 Exhibit 99.1


USANA Health Sciences Reports Second Quarter Results

SALT LAKE CITY--(BUSINESS WIRE)--July 26, 2022--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended July 2, 2022.

Key Financial & Operating Results

  • Second quarter net sales were $264 million as compared with $337 million during the second quarter of the prior year.
  • Second quarter diluted EPS totaled $1.00 versus $1.87 during the second quarter of 2021.
  • Company reiterates fiscal 2022 net sales and diluted EPS outlook of $1.015 billion to $1.065 billion and $3.85 to $4.45, respectively.

Q2 2022 Financial Performance

Consolidated Results

Net Sales

$264 million

  • -21% vs. prior-year quarter
  • -18% constant currency vs. prior-year quarter
  • -$10.9 million YOY FX impact, or -3%
  • Flat sequentially in constant currency

Diluted EPS

$1.00

  • -47% vs. prior-year quarter
  • -13% sequentially
  • Diluted shares of 19.2 million, -6% year-over-year

Active Customers

559,000

  • -14% vs. prior-year quarter
  • +1% sequentially

“As indicated in our preliminary results release on July 6th, we continue to experience COVID-related disruptions in several key markets, including mainland China. This caused participation in sales programs, Active Customer counts, and financial performance to come in lower than anticipated,” said Kevin Guest, Chief Executive Officer and Chairman of the Board. “Although many of these disruptions were outside of our control, and while we faced a tough year-over year comparable due to the timing of a successful sales program in 2021, our second quarter results were not up to our standards. Nevertheless, we remain committed to our business strategy which we believe will deliver sustained, long-term growth in customer counts, net sales, and EPS. Important elements of this strategy include (1) enhancing digital experience for our customers to improve the overall online shopping experience; (2) improving Associate onboarding and training to help drive and sustain customer growth; (3) exploring additional promotions and incentives on a market-specific basis; (4) launching experience centers in mainland China to promote growth in this key market; and (5) pursuing accretive business development opportunities.


"During the quarter, we streamlined our Associate onboarding program and provided Associates with additional tools to help them more efficiently and effectively setup and operate their businesses. Our team also launched improvements to our China shopping app to further improve the online shopping experience in that market. Although it takes time to recapture momentum, we are confident these strategies will deliver long-term growth.”

Q2 2022 Regional Results:

Asia Pacific Region

Net Sales

$217 million

  • -22% vs. prior-year quarter
  • -18% constant currency vs. prior-year quarter
  • +3% constant currency sequentially
  • 82% of consolidated net sales

Active Customers

438,000

  • -15% vs. prior-year quarter
  • +4% sequentially

Asia Pacific Sub-Regions

Greater China

Net Sales

$141 million

  • -15% vs. prior-year quarter
  • -13% constant currency vs. prior-year quarter

Active Customers

278,000

  • -8% vs. prior-year quarter
  • +9% sequentially

North Asia

Net Sales

$29 million

  • -23% vs. prior-year quarter
  • -13% constant currency vs. prior-year quarter

Active Customers

57,000

  • -14% vs. prior-year quarter
  • Flat sequentially

Southeast Asia Pacific

Net Sales

$48 million

  • -37% vs. prior-year quarter
  • -33% constant currency vs. prior-year quarter

Active Customers

103,000

  • -29% vs. prior-year quarter
  • -6% sequentially

Americas and Europe Region

Net Sales

$47 million

  • -19% vs. prior-year quarter
  • -17% constant currency vs. prior-year quarter
  • -13% constant currency sequentially
  • 18% of consolidated net sales

Active Customers

121,000

  • -13% vs. prior-year quarter
  • -7 % sequentially

Balance Sheet and Share Repurchase Activity

The Company ended the quarter with $230 million in cash and cash equivalents and did not repurchase any shares during the quarter. As of July 2, 2022, the Company had approximately $83 million remaining under the share repurchase authorization.

Fiscal 2022 Outlook

The Company is reiterating its net sales and earnings per share outlook for fiscal year 2022, which was updated on July 6, 2022.

Fiscal Year 2022 Outlook

 

Range

Consolidated Net Sales

$1.015 - $1.065 billion

Diluted EPS

$3.85 - $4.45

Doug Hekking, Chief Financial Officer, said, “While we remain optimistic that our strategies will generate future growth, we believe we will continue to face a challenging operating environment in the second half of the year. Moreover, we will do so with a lower-than-anticipated Active Customer base, which will impact our top and bottom-line results for the period. Although COVID-related disruptions and inflationary pressures remain difficult, we remain steadfast in pursing investments to deliver on our business objectives. We will also continue to align our cost structure with sales performance. Despite a challenging operating environment, our debt-free balance sheet remains healthy, and we are on pace to generate meaningful cash flow for the year.”

Management Commentary Document and Conference Call

For more information on the USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, July 27, 2022 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, followed by a questions and answers session.

Non-GAAP Financial Measures

The Company prepares its financial statements using U.S. generally accepted accounting principles (“GAAP”). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, “Financial Results”) are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates (“FX”) and help facilitate period-to-period comparisons of the Company’s Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results.


About USANA

USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, and Italy. More information on USANA can be found at www.usana.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: uncertainty related to the magnitude, scope and duration of the impact of the COVID-19 pandemic (“COVID-19”) to our business, operations and financial results; the further spread of, and regulatory measures or voluntary actions that may be put in place to limit the spread of, COVID-19 in the markets where we operate, including restrictions on business operations, shelter at home, or social distancing requirements; the potential for a resurgence of COVID-19 spread in any of our markets in the future; the impact of COVID-19 on the domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; regulatory risk in China in connection with the health products and direct selling business models; regulatory risk in the United States in connection with the direct selling business model; potential negative effects of deteriorating foreign and/or trade relations between the United States and China; potential negative effects from geopolitical relations and conflicts, including the Russia-Ukraine conflict; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; global economic conditions generally, including increasing inflationary pressure around the world and any negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model; adverse publicity risks globally; risks associated with our international expansion and operations; and uncertainty relating to the fluctuation in U.S. and other international currencies. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.


USANA Health Sciences, Inc.
Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)








 


Quarter Ended
Six Months Ended


2-Jul-22
3-Jul-21
2-Jul-22
3-Jul-21








 
Net sales

$

264,474

 


$

336,837


$

537,341


$

644,813

Cost of sales

 

49,517

 


 

57,014


 

100,900


 

114,665

Gross profit

 

214,957

 


 

279,823


 

436,441


 

530,148

Operating expenses:







Associate incentives

 

119,204

 


 

153,863


 

238,824


 

288,358

Selling, general and administrative

 

66,387

 


 

72,240


 

135,184


 

143,873

Earnings from operations

 

29,366

 


 

53,720


 

62,433


 

97,917

Other income (expense), net

 

(58

)


 

590


 

162


 

729

Earnings before income taxes

 

29,308

 


 

54,310


 

62,595


 

98,646

Income taxes

 

10,151

 


 

16,076


 

20,969


 

29,791

NET EARNINGS

$

19,157

 


$

38,234


$

41,626


$

68,855









 








 
Earnings per share - diluted

$

1.00

 


$

1.87


$

2.15


$

3.31

Weighted average shares outstanding - diluted

 

19,244

 


 

20,446


 

19,362


 

20,771


USANA Health Sciences, Inc.
Consolidated Balance Sheets
(In thousands)
(Unaudited)




 


As of
As of


2-Jul-22
1-Jan-22
ASSETS



Current Assets



Cash and cash equivalents

$

230,370


$

239,832

Inventories

 

84,171


 

98,318

Prepaid expenses and other current assets

 

27,536


 

26,967

Total current assets

 

342,077


 

365,117





 
Property and equipment, net

 

97,827


 

101,780

Goodwill

 

17,402


 

17,668

Intangible assets, net

 

34,371


 

30,442

Deferred tax assets

 

11,265


 

4,839

Other assets

 

55,017


 

57,894

Total assets

$

557,959


$

577,740





 
LIABILITIES AND STOCKHOLDERS' EQUITY



Current Liabilities



Accounts payable

$

10,175


$

13,508

Other current liabilities

 

123,419


 

147,282

Total current liabilities

 

133,594


 

160,790





 
Deferred tax liabilities

 

5,142


 

7,497

Other long-term liabilities

 

15,542


 

14,329





 
Stockholders' equity

 

403,681


 

395,124

Total liabilities and stockholders' equity

$

557,959


$

577,740


USANA Health Sciences, Inc.
Sales by Region
(In thousands)
(Unaudited)
















 


Quarter Ended









July 2, 2022
July 3, 2021
Change from prior year
Currency impact on sales
% change excluding currency impact
Asia Pacific















Greater China

$

140,775


53.2

%


$

165,416


49.1

%


$

(24,641

)


(14.9

%)


$

(3,062

)


(13.0

%)

Southeast Asia Pacific

 

47,830


18.1

%


 

76,101


22.6

%


 

(28,271

)


(37.1

%)


 

(3,341

)


(32.8

%)

North Asia

 

28,803


10.9

%


 

37,438


11.1

%


 

(8,635

)


(23.1

%)


 

(3,632

)


(13.4

%)

Asia Pacific Total

 

217,408


82.2

%


 

278,955


82.8

%


 

(61,547

)


(22.1

%)


 

(10,035

)


(18.5

%)

















 
Americas and Europe

 

47,066


17.8

%


 

57,882


17.2

%


 

(10,816

)


(18.7

%)


 

(863

)


(17.2

%)



$

264,474


100.0

%


$

336,837


100.0

%


$

(72,363

)


(21.5

%)


$

(10,898

)


(18.2

%)


Active Associates by Region(1)
(Unaudited)








 


As of


July 2, 2022
July 3, 2021
Asia Pacific







Greater China

77,000


32.9

%


88,000


29.3

%

Southeast Asia Pacific

69,000


29.5

%


104,000


34.7

%

North Asia

36,000


15.4

%


42,000


14.0

%

Asia Pacific Total

182,000


77.8

%


234,000


78.0

%









 
Americas and Europe

52,000


22.2

%


66,000


22.0

%



234,000


100.0

%


300,000


100.0

%









 
Active Preferred Customers by Region (2)
(Unaudited)








 


As of


July 2, 2022
July 3, 2021
Asia Pacific







Greater China

201,000


61.8

%


215,000


61.1

%

Southeast Asia Pacific

34,000


10.5

%


40,000


11.4

%

North Asia

21,000


6.5

%


24,000


6.8

%

Asia Pacific Total

256,000


78.8

%


279,000


79.3

%









 
Americas and Europe

69,000


21.2

%


73,000


20.7

%



325,000


100.0

%


352,000


100.0

%


(1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale.

(2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

 

Contacts

Investor contact:
Andrew Masuda
Investor Relations
(801) 954-7201
investor.relations@usanainc.com

Media contact:
Dan Macuga
Public Relations
(801) 954-7280

EX-99.2 3 a52792490ex992.htm EXHIBIT 99.2
Exhibit 99.2



 
 USANA Health Sciences, Inc. 
 July 26, 2022
                                                                                                                                           
Q2 2022 Management Commentary
 

Key Financial & Operating Results


Second quarter net sales were $264 million as compared with $337 million during the second quarter of the prior year.


Second quarter diluted EPS totaled $1.00 versus $1.87 during the second quarter of 2021.


Company reiterates fiscal 2022 net sales and diluted EPS outlook of $1.015 billion to $1.065 billion and $3.85 to $4.45, respectively.

Overview
 
As indicated in our preliminary results release on July 6th, we continue to experience COVID-related disruptions in several key markets, including mainland China. This caused participation in sales programs, Active Customer counts, and financial performance to come in lower than anticipated. Although many of these disruptions were outside of our control, and while we faced a tough year-over year comparable due to the timing of a successful sales program in 2021, our second quarter results were not up to our standards. Additionally, unfavorable foreign currency exchange rate movement negatively impacted year-over-year net sales performance by approximately 320 basis points.
 
The operating environment contributed to several business decisions, including the decision to increase inventory levels over the last couple of years to mitigate potential supply chain disruptions. We also continued to experience inflationary pressure across many areas of our business that have negatively impacted our operating margin and this is expected to continue over the next several quarters. Consequently, efforts are underway to align spending with current and expected sales performance, yet will allow for prioritized investments in areas of strategic importance.
 

Although we believe that we will continue to face short-term pressure on our operating performance, we remain committed to our business strategy, which we believe will position the Company to deliver sustainable long-term growth in customer counts, net sales and EPS. Our healthy balance sheet enables the flexibility to continue investing in our business to support efforts to create long-term value for our stakeholders.
 
During the quarter, we made progress on our digital strategy on several fronts. We introduced enhancements to our Associate onboarding program and provided Associates with additional tools to efficiently and effectively setup and operate their business. We also continued to invest in and enhance the digital experience for our customers around the world and launched improvements to our China shopping app to further improve the online shopping experience in this market.
 
In a few weeks, we will celebrate our 30th Anniversary at our upcoming Global Convention. This will be a hybrid event in Salt Lake City with an expected in-person attendance of approximately 4,000 Associates. We have select events and modest promotional activity planned in conjunction with this celebration to help generate excitement and momentum in the business.
 
Q2 2022 Results
 
Consolidated Results
Net Sales
$264 million
•-21% vs. prior-year quarter
•-18% constant currency vs. prior-year quarter
•-$10.9 million YOY FX impact, or -3%
•Flat sequentially in constant currency
Diluted EPS
$1.00
•-47% vs. prior-year quarter
•-13% sequentially
•Diluted shares of 19.2 million, -6% year-over-year
Active Customers
559,000
•-14% vs. prior-year quarter
•+1% sequentially
 
2
Balance Sheet and Share Repurchase Activity
 
We ended the quarter with $230 million in cash and cash equivalents and did not repurchase any shares during the quarter. As of July 2, 2022, the Company had approximately $83 million remaining under the share repurchase authorization.
 
Quarterly Income Statement Discussion
 
Gross margin decreased 180 basis points from the prior year to 81.3% of net sales. The decrease can be attributed to the negative impact of currency exchange rates, higher inventory valuation adjustments and the loss of leverage on fixed-period costs due to lower net sales. The ongoing inflationary pressure on the price of material and labor also impacted gross margins in the current-year quarter. These cost pressures were offset, in part, by favorable changes in geographic sales mix.
 
Associate Incentives decreased 60 basis points from the prior year to 45.1% of net sales. The modest decrease reflects lower incentive and promotional expenses during the current-year quarter as compared to the global sales program offered in each of our markets during the prior year’s second quarter.
 
Selling, General and Administrative expenses increased 360 basis points from the prior year to 25.1% as a percentage of net sales. The increase is largely due to loss of leverage on lower year-over-year net sales. On an absolute basis, SG&A expenses decreased $5.9 million compared to the prior year due, in part, to variable-based expenses.
 
The effective tax rate increased to 34.6% from the 29.6% reported in the prior-year quarter, largely due to a change in distribution of pre-tax income generated by market. The year-to-date effective tax rate of 33.5% is in line with expectations for the full year.
 
 
3
 
Regional Financial Results
 
Asia Pacific Region
Net Sales
$217 million
•-22% vs. prior-year quarter
•-18% constant currency vs. prior-year quarter
•+3% constant currency sequentially
•82% of consolidated net sales
Active Customers
438,000
•-15% vs. prior-year quarter
•+4% sequentially

 
Asia Pacific Sub-Regions
Greater China
Net Sales
$141 million
•-15% vs. prior-year quarter
•Constant currency net sales: -13%
Active Customers
278,000
•-8% vs. prior-year quarter
•+9% sequentially
North Asia
Net Sales
$29 million
•-23% vs. prior-year quarter
•Constant currency net sales: -13%
Active Customers
57,000
•-14% vs. prior-year quarter
•Flat sequentially
Southeast Asia Pacific
Net Sales
$48 million
•-37% vs. prior-year quarter
•Constant currency net sales: -33%
Active Customers
103,000
•-29% vs. prior-year quarter
•-6% sequentially
 
Greater China: Net sales and local currency sales in mainland China decreased 15% and 13% year-over-year, respectively, while Active Customers in this market decreased 9%. Sequentially, net sales in mainland China increased 7% and Active Customers increased 10%.
 
4
We continued to experience a challenging operating environment in China, as COVID-related lockdowns and restrictions in several areas persisted throughout the quarter, making it difficult to hold small in-person meetings. Consequently, the response to promotional activity in mainland China was meaningfully below our internal expectations. We currently have limited visibility in this key market as COVID-related disruptions continue to have a pronounced impact on our business. Despite the current difficulties, we remain committed to making strategic investments and are optimistic in the long-term growth prospects of this key market
 
North Asia: Net sales and local currency sales in South Korea decreased 23% and 13% year-over-year, respectively. On a sequential basis, net sales and local currency sales declined 4% and grew 1%, respectively. Weaker-than-anticipated response to promotional activity, which was partially attributable to COVID-related disruptions in South Korea was the key driver of the sales declines during the second quarter.
 
Southeast Asia Pacific: Key markets in this sub-region continue to be impacted by local restrictions and lockdowns. Additionally, concerns around a slowdown in local economies impacted consumer sentiment and purchasing behavior. Local currency sales and Active Customers in Malaysia declined 28% and 21% year-over-year, respectively. Sequentially, local currency sales decreased 1% and Active Customers were flat. The Philippines reported local currency sales and Active Customers declines of 48% and 42%, respectively. On a sequential basis, local currency sales and Active Customers declined 20% and 11%, respectively.
 
Americas and Europe Region
Net Sales
$47 million
•-19% vs. prior-year quarter
•-17% constant currency vs. prior-year quarter
•-13% constant currency sequentially
•18% of consolidated net sales
Active Customers
121,000
•-13% vs. prior-year quarter
•-7 % sequentially
 
Americas and Europe Region: Year-over-year net sales performance for key markets in this region reflects the difficult comparison due to the strong response to last year’s global sales program. Net sales in the United States and Canada declined 10% and 26% year-over-year respectively.
 
5
Outlook and 2022 Operating Strategy
 
We are reiterating our consolidated net sales and earnings per share outlook for fiscal year 2022, which was updated on July 6, 2022.
 
Fiscal Year 2022 Outlook
 
Range
Consolidated Net Sales
$1.015 - $1.065 billion
Diluted EPS
$3.85 - $4.45
 
Our revised outlook for the year reflects:




An unfavorable currency exchange rate impact on net sales of approximately $40 million (previously $16 million);
 

An operating margin in the range of 11% and 12% (previously 13.0% and 13.6%);
 

An annual effective tax rate of 33.5% (previously 32.5%); and
 

An annualized diluted share count of 19.3 million (previously 19.6 million).
 
We remain committed to our strategic growth objectives, including: (1) enhancing the digital experience for our customers to improve the overall online shopping experience; (2) improving Associate onboarding and training to help drive and sustain customer growth; (3) exploring additional promotional and incentive offerings on a market-specific basis; (4) driving growth in our China market, which includes launching experience centers to help facilitate our strategic growth plan for this key market and; (5) pursuing accretive business development opportunities.
 

Kevin Guest
CEO
 
Douglas Hekking
CFO
 
6
Safe Harbor
 
This Management Commentary contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: uncertainty related to the magnitude, scope and duration of the impact of the COVID-19 pandemic (“COVID-19”) to our business, operations and financial results; the further spread of, and regulatory measures or voluntary actions that may be put in place to limit the spread of, COVID-19 in the markets where we operate, including restrictions on business operations, shelter at home, or social distancing requirements; the potential for a resurgence of COVID-19 spread in any of our markets in the future; the impact of COVID-19 on the domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; regulatory risk in China in connection with the health products and direct selling business models; regulatory risk in the United States in connection with the direct selling business model; potential negative effects of deteriorating foreign and/or trade relations between the United States and China; potential negative effects from geopolitical relations and conflicts, including the Russia-Ukraine conflict; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; global economic conditions generally, including increasing inflationary pressure around the world and any negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model; adverse publicity risks globally; risks associated with our international expansion and operations; and uncertainty relating to the fluctuation in U.S. and other international currencies. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.
7
Non-GAAP Financial Measures
 
The Company prepares its financial statements using U.S. generally accepted accounting principles (“GAAP”). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, “Financial Results”) are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates (“FX”) and help facilitate period-to-period comparisons of the Company’s Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results.
 

   
Investor contact:
Andrew Masuda
 
Investor Relations
 
(801) 954-7210
 
investor.relations@usanainc.com
Media contact:
Dan Macuga
 
Public Relations
 
801-954-7280

8